Table 1.

Terminology for anticoagulation and antiplatelet therapy in arterial thrombosis

	Term	Abbreviation	Meaning
Combination therapy	Dual antiplatelet therapy	DAPT	Aspirin 81 mg + P2Y12 inhibitor
	Dual antithrombotic therapy	DAT	Anticoagulation + one antiplatelet agent (commonly in patients with AF and CAD)
	Dual pathway inhibition	DPI	Very low-dose anticoagulation + antiplatelet agent(s)
	Triple antithrombotic therapy Triple therapy	TAT TT	Anticoagulation + 2 antiplatelet agents
DOAC dosing	Standard-dose DOAC	—	Apixaban 5 mg BID Dabigatran 150 mg BID Dabigatran 220 mg daily Edoxaban 60 mg daily Rivaroxaban 20 mg daily
	Reduced-dose DOAC*	—	Apixaban 2.5 mg BID† Rivaroxaban 15 mg daily‡
	Low dose DOAC Prophylactic dose DOAC	—	Apixaban 2.5 mg BID Rivaroxaban 10 mg daily
	Very low-dose DOAC	—	Rivaroxaban 2.5 mg BID

^* Dosing regimens for patients with renal impairment, low body weight, and/or advanced age. See apixaban^† and rivaroxaban^‡ details.

^† Dosing for patients with AF who meet 2 of the following 3 criteria: creatinine ≥1.5 mg/dL, age ≥80 years, and weight ≤60 kg.

^‡ Dosing used in patients with AF with creatinine clearance ≤50 mL/min.

AF, atrial fibrillation; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; BID, twice daily.